The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
REGULATORY
Industry Veteran Prods Appropriate Evaluation for Innovation: LDP Confab
Japan should appropriately reward innovation to foster its pharmaceutical sector, departing from frequent changes being made to its drug pricing system, which have eroded predictability in the market, industry veteran Haruhiko Hirate told ruling party lawmakers on April 15. Mr…
To read the full story
Related Article
- Lawmakers See No Ultimate Goal in New Pharma Industry Vision
August 6, 2021
- New Pharma Industry Vision to Push Predictability for Investment Recovery: Draft Outline
August 3, 2021
- LDP Project Team on Drug Discovery Capabilities Likely to Meet Aug. 4
July 28, 2021
- LDP Project Team Submits Proposal to Boost Drug Discovery Capabilities
May 24, 2021
- LDP Project Team Urges Overhaul of Unpredictable Pricing System: Proposal
May 14, 2021
- LDP’s Project Team Calls for Audacious Gov’t Investment Targets for Drug Discovery Capabilities
April 30, 2021
- Trade Groups Push Proper Pricing of Innovative Drugs to Restore Attractiveness of Japan: LDP Confab
March 19, 2021
- MHLW Presents Views on “Pharma Industry Vision 2021” to LDP’s Project Team
March 8, 2021
- LDP to Set Up Project Team to Strengthen Pharma Sector, Eyes Proposal in May
February 22, 2021
REGULATORY
- MHLW to Investigate Pharmaceutical Ad Regulations in US, Europe
March 18, 2025
- MHLW Council OKs Public Knowledge Filing for Anaemetro’s Pediatric Use
March 17, 2025
- PMDA Reviewing Safety Risks of Paxlovid/Xtandi Concurrent Use
March 17, 2025
- MHLW Panel OKs List of “High-Priority” Vaccines, including Norovirus Jabs
March 14, 2025
- JPA Asks for Price Penalty for High-Cost Meds with Packaging Unaligned to Dosing
March 14, 2025
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…